Research programme: vitronectin receptor antagonists - Uriach
Alternative Names: Vitronectin receptor antagonists research programme - UriachLatest Information Update: 20 Jan 2004
At a glance
- Originator Uriach
- Class
- Mechanism of Action Integrin alphaVbeta3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Coronary artery restenosis; Osteoporosis; Vascular restenosis
Most Recent Events
- 20 Jan 2004 Discontinued - Preclinical for Cancer in Spain (unspecified route)
- 20 Jan 2004 Discontinued - Preclinical for Coronary artery restenosis in Spain (unspecified route)
- 20 Jan 2004 Discontinued - Preclinical for Osteoporosis in Spain (unspecified route)